COVID-19: Johnson & Johnson vaccine trial halted due to sick participant

WASHINGTON | Pharmaceutical group Johnson & Johnson announced on Monday the suspension of its clinical trial of a vaccine against COVID-19, one of the participants having fallen ill.

• Read also: All developments in the COVID-19 pandemic

“We have temporarily halted additional dosing in all of our clinical trials of an investigational COVID-19 vaccine, including the entire Phase 3 trial, due to unexplained illness in one participant,” said the group said in a statement.

This suspension leads to the closure of the online registration system set up at the end of September to recruit 60,000 participants in the context of phase 3 of the trial, while the independent committee for patient safety was seized.

Serious adverse events are “an expected component of any clinical study, especially large studies,” Johnson & Johnson said. The protocols in force in the company provide for the suspension of a study to determine if the serious adverse event is related to the drug being evaluated and if it is possible to resume the trial.

About Victoria Smith

Victoria Smith who hails from Toronto, Canada currently runs this news portofolio who completed Masters in Political science from University of Toronto. She started her career with BBC then relocated to TorontoStar as senior political reporter. She is caring and hardworking.

Check Also

Can COVID Justify This $ 23M Contract?

The health emergency has a broad back to justify a $ 23 million IT contract …

Leave a Reply

Your email address will not be published. Required fields are marked *